Artiva Biotherapeutics (NASDAQ:ARTV) CEO Sells $422,000.64 in Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 61,696 shares of the stock in a transaction on Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $422,000.64. Following the completion of the sale, the chief executive officer owned 1,543,069 shares of the company’s stock, valued at $10,554,591.96. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Fred Aslan also recently made the following trade(s):

• On Tuesday, October 6th, Fred Aslan sold 23,463 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $7.20, for a total value of $168,933.60.
• On Tuesday, September 8th, Fred Aslan sold 23,429 shares of Artiva Biotherapeutics stock. The stock was sold at an average price of $10.92, for a total value of $255,844.68.

Artiva Biotherapeutics Trading Down 2.9%

NASDAQ ARTV opened at $6.80 on Friday. The firm has a market capitalization of $332.45 million, a PE ratio of -2.06 and a beta of 2.40. The business’s 50-day moving average price is $9.89 and its two-hundred day moving average price is $9.25. Artiva Biotherapeutics, Inc. has a 12 month low of $2.71 and a 12 month high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). As a group, analysts forecast that Artiva Biotherapeutics, Inc. will post -2.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ARTV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price target on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $22,827,049. Blue Owl Capital Holdings LP acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at $8,483,000. BlackRock Inc. bought a new position in Artiva Biotherapeutics during the second quarter worth $6,739,000. Nantahala Capital Management LLC bought a new position in Artiva Biotherapeutics during the second quarter worth $2,910,000. Finally, Alyeska Investment Group L.P. grew its holdings in Artiva Biotherapeutics by 173.6% in the second quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company’s stock worth $2,654,000 after purchasing an additional 173,615 shares during the period.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc (NASDAQ:ARTV) is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to produce off-the-shelf cell therapies that can be manufactured at scale and administered without using cells collected from each individual patient.

Artiva’s lead investigational product, AlloNK, also known as AB-101, is an allogeneic NK cell therapy being evaluated in combination with rituximab for autoimmune conditions, including systemic lupus erythematosus and lupus nephritis.